{"preliminary_commentary":{"by_channel":{"x_thread":6,"youtube":1,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05722015\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"NCT05722015","nct_id":"NCT05722015","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05722015. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants with treatment-naïve metastatic NSCLC receive 790 mg of Pembrolizumab Formulated With Berahyaluronidase Alfa via subcutaneous (SC) injection on Day 1 of each 6-week cycle for 18 cycles (up to approximately 108 weeks) in combination with platinum doublet chemotherapy.","label":"Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","type":"EXPERIMENTAL"},{"description":"Participants with treatment-naïve metastatic NSCLC receive 400 mg pembrolizumab intravenous (IV) infusion in combination with platinum doublet chemotherapy.","label":"Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-05-22","type":"ESTIMATED"},"conditions":["Metastatic Non-small Cell Lung Cancer"],"enrollment":{"count":377,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pembrolizumab Formulated with Berahyaluronidase Alfa","otherNames":["MK-3475A"],"type":"BIOLOGICAL"},{"name":"Pemetrexed","otherNames":["Alimta"],"type":"DRUG"},{"name":"Cisplatin","otherNames":["Platinol-AQ"],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel","otherNames":["Taxol"],"type":"DRUG"},{"name":"Nab-paclitaxel","otherNames":["Albumin-bound paclitaxel"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["MK-3475, KEYTRUDA"],"type":"BIOLOGICAL"},{"name":"Filgrastim","otherNames":[],"type":"DRUG"},{"name":"Pegylated filgrastim","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-26","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-07-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose","timeFrame":"Cycle 1: Arm 1: Day 1: Predose and Days 2, 3, 4, 5, 6, 7, 10, 15, 29, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4, 15, 29, and 42 postdose (cycle length = 42 days)"},{"measure":"Cycle 3: Trough Serum Concentration (Ctrough) of Pembrolizumab at Steady State","timeFrame":"Cycle 3: Arm 1: Day 1: Predose and Days 4, 10, and 42 postdose; Arm 2: Day 1: Predose and at the end of infusion, Days 4 and 42 postdose (cycle length = 42 days)"}],"references":[{"citation":"Felip E, Rojas CI, Schenker M, Kowalski DM, Casarini IA, Csoszi T, Sendur MAN, Martins J, Calles Blanco A, Wang CC, Wang M, Ramirez Fallas RAL, Yoshioka H, Nair S, Song X, Deng X, Lala M, Eiras R, Takahashi T. Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial. Ann Oncol. 2025 Jul;36(7):775-785. doi: 10.1016/j.annonc.2025.03.012. Epub 2025 Mar 27.","pmid":"40157574","type":"RESULT"}],"start_date":{"date":"2023-02-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)","url":"https://clinicaltrials.gov/study/NCT05722015"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05722015"}